Sentences with phrase «molecule therapies for»

Some research efforts are closer to clinical implementation, including developing improvements in clinical management of rare diseases and trials of small molecule therapies for inherited and mosaic genetic disorders.

And Xenon, a Vancouver - based biotech, completed a US$ 31 - million private equity financing last April that will allow it to further develop its product pipeline, which consists of small - molecule therapies for select neurological, cardiovascular and metabolic diseases.

Not exact matches

Researchers at the Center for Engineering MechanoBiology (CEMB), an NSF Science and Technology Center at the University of Pennsylvania, study plants like this Arabidopsis thaliana to learn how molecules, cells and tissues integrate mechanics within plant and animal biology, with the aim of creating new materials, biomedical therapies and agricultural technologies.

Dr. Sharp and project co-leader Joshua Nosanchuk, M.D., professor of medicine at Einstein and attending physician, infectious diseases at Montefiore Medical Center, developed a wound - healing therapy that uses molecules of silencing RNA (siRNAs) specific for FL2.

Professor Ali Tavassoli, who led the study with colleague Dr. Ishna Mistry, explains: «In an effort to better understand the role of HIF - 1 in cancer, and to demonstrate the potential for inhibiting this protein in cancer therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF - 1 inhibiting molecule when placed in a hypoxic environment.

The Mast Cells and Basophiles: Targets for Innovative Therapies project, funded by COST funding BM1007 of the EU, brings together European experts focusing on the identification of new target molecules for drug development, including allergy drugs.

Treatment for advanced melanoma has seen success with targeted therapies — drugs that interfere with division and growth of cancer cells by targeting key molecules — especially when multiple drugs are used in combination.

Initial results were discouraging: attempts to simply replace the protein therapies with small - molecule drugs that hit the same targets largely failed, says Saeed Fatenejad, a rheumatologist at Pfizer who is responsible for clinical development of tasocitinib.

Dr. Lazaridis says this molecule therefore should be further examined as a target of therapy for the disease.

Green explains that siRNAs must be encapsulated in particles that are different from those used to carry DNA because siRNAs are about 250 times smaller than the DNA molecules usually used for gene therapy.

While this is hopeful news for some patients, more research is needed to further understand not only IL13RA2, but other molecules in breast cancers that may guide diagnosis, prognosis, and ultimately drug development and therapy.

«Molecule common in some cancers, rheumatoid arthritis leads to potential therapy for both.»

And because their surfaces can be easily tailored to facilitate the attachment of various medicinal molecules, nanodiamonds have tremendous potential for the delivery of a vast range of therapies.

But rather than delivering the entire gene for the clotting - factor proteins to cells, as most gene therapies do, the researchers used the viruses to engineer immune - regulating B cells to express a fragment of the clotting factor fused to an immune molecule called an immunoglobulin.

Advances in understanding the cells and molecules that transmit pain signals are providing new targets for drugs that could relieve various kinds of pain — including those poorly controlled by existing therapies

A fruit fly model of Duchenne muscular dystrophy allowed Ruohola - Baker's lab to rapidly score small molecule therapy candidates for raising the level of sphingosine 1 - phosphate.

«But we still have a far way to go: To reliably use this type of photoswitchable molecules for a photodynamic therapy of patients, numerous other studies have to be carried out in cooperation with our partners in Kiev.»

Gain an understanding of the specific molecules and pathways that are the targets for rationally designed therapies

Small molecule drugs can be screened or designed to increase telomerase activity exclusively within stem cells for disease treatment as well as anti-aging therapies without increasing the risk of cancer.

She's also created artificial bone materials, targets for tuberculosis therapy, cell microarray platforms, and a cell nanoinjector, a device used to inject molecules into living cells.

For all the advantages of these extended - life molecules, the researchers predict that they will be supplanted in perhaps a decade by advances in gene therapy, which will enable people with haemophilia to produce their own clotting factors.

A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy.

The new, extended therapy combines recombinant factor VIII with a fusion protein that allows the molecule to remain in the circulation longer — translating into a need for less frequent treatment.

The therapy has been in development for six years and involves a first - in - class molecule designed by the team.

Recently, scientists have uncovered many of the molecules in the pathway that control the switch from fetal to adult hemoglobin, opening the door to new therapies; if you could prevent the switch from happening, or reverse it, and let people with sickle cell disease use fetal hemoglobin for life, that should reduce symptoms.

However, Professor Auguste's team, discovered the overexpression of intercellular adhesion molecule - 1 (ICAM - 1) in human TNBC cell lines and tissues, and demonstrated that it is a potential molecular target and biomarker for TNBC therapy and diagnosis.

To devise a potential new therapy, the investigators engineered a population of neural stem cells to express a potent version of a gene called TRAIL, which codes for a molecule that activates cell - death - inducing receptors found only on the surface of cancer cells.

Indeed, inhibiting CXCR4 function systemically with the small molecule antagonist plerixafor results in the peripheral mobilization of hematopoetic stem cells, thus mitigating the potential of such therapy for long - term anti-retroviral therapy.

«We are also developing novel small molecules to selectively block the receptor for FnEDA as a potential anti-fibrotic therapy in humans.»

«Given the alarming trend of resistance to our current antimalarial therapies, this is really an exciting finding,» says Dr. Mota, the senior author of the study, «and we are already working to develop Torin molecules suitable for clinical trials of antimalarial activity in humans.»

Neoantigens are molecules on cell's surfaces that are produced by DNA mutations that are present in cancer cells but not in normal cells, making neoantigens ideal targets for immune therapy against cancer, say the scientists.

«Being able to target a specific site in the genome is essential for the next generation of rationally designed therapies, and the lessons we've learned have changed the way we design molecules to target individual genomes,» says Ansari.

Our methodology enables the discovery of unique biomarkers at a single molecule level for personalized therapy approaches.

«It is amazing that we can make one genetic adjustment and positively impact on lifespan and intestinal health, understanding more about the underlying molecules at work here promises new strategies for anti-ageing therapies,» says Dr Jennifer Tullet from the University of Kent.

We are currently developing small molecule Nav1.1 activators that increase Nav1.1 currents and interneuron - dependent gamma oscillations in vitro and in vivo to develop novel therapies for conditions with impaired interneuron function, including AD and Dravet syndrome.

The cells generated in the Zeng lab may not only provide a potential unlimited source for cell replacement therapy for Parkinson's disease, but also offer an unprecedented opportunity to develop screening models for assessing small molecule drugs and to clarify the mechanisms of disease.

Our collaborative approach and deep scientific and regulatory understanding of each molecule type helps us shape the best strategy for bringing a novel therapy to market and design custom studies and programs that reduce risk and accelerate timelines.

Yet one thing is clear: Major pharmaceutical manufacturers, originally skeptical about the prospects for large - molecule therapies, have long since joined the race to develop the treatments, acquiring, merging or partnering with small companies working on mAbs and other biologics.

This will fast - track new immune - modulating therapies for cancer patients by discovering and developing small molecule product candidates against immuno - oncology targets.

The mission of the Institute for Applied Cancer Science (IACS) is to apply scientific knowledge of mechanisms driving tumor development and maintenance into the development of impactful small molecule cancer therapies.

Our research will contribute to a better mechanistic understanding of the microbes that live in our body, leading to the discovery of druggable small molecules, new targets for antibacterial therapy and beneficial bacterial strains that can be employed for intervention therapies.

To build upon the encouraging early discoveries, Helmsley renewed and expanded its Crohn's funding for the Institute in 2013 to begin new work with three major aims: 1) continue studies of individual genes to determine how genetic differences between Crohn's patients and healthy individuals contribute to the disease; 2) evaluate promising small molecules in disease - relevant studies and prioritize insights from genetics to help develop novel therapeutics; and 3) begin basic experimentation in animal models with Crohn's disease to provide the data necessary to begin testing new therapies in humans.

A biopsy of each patient's cancer will be screened for 600 genes as well as protein expression to uncover molecules and pathways that are driving the cancer and to predict a patient's response to chemotherapy or other tailored therapy.

The SMDC has allowed Gladstone scientists to design molecules to modulate the functions of proteins or specific cellular phenotypes and, most significantly, screen for drugs that could be used as therapies for disease.

The company's lead candidate, GLN - 1001, is a first - in - class, orally available oncolytic small molecule, currently being developed as a potentially disease modifying therapy for glioblastoma by targeting specific vulnerabilities in tumor cells.

In melanoma, the MAPK and PI3K pathways are primary targets for therapy, but other pathways are also explored for inhibition by small molecule compounds.

The platform serves as a potential way to help researchers quickly discover new carriers for a broad range of treatments, from small molecules to gene therapies.

We are interested in the mechanistic function and structure of antimicrobial / antifungal proteins and peptides and the identification of target molecules for the development of new antimicrobial / antifungal therapies.

Figure 2: Comparing the patent landscapes for induced pluripotent stem cell (top) and a small - molecule drug candidate (MK - 1775, bottom) highlights need for intellectual property consideration in cell therapy DST — search and analysis conducted in Thomson Innovation and Thomson Data Analyzer (TDA) software from Thomson Reuters; themescape maps produced using TDA.

Xavier and his team will also devote time to advancing their research by continuing to develop assays to screen molecules for potential therapies, study the microbiome, and compose a map of each cell in the gut in both healthy individuals and IBD patients.